Botulinum toxin as an initial therapy for management of sixth nerve palsies caused by nasopharyngeal carcinomas

Abstract

Purpose

The purpose of this study is to evaluate the efficacy and safety of botulinum toxin injection as a primary treatment for strabismus in a cohort of patients with nasopharyngeal carcinoma (NPC)-related chronic sixth nerve palsy.

Patients and methods

We retrospectively reviewed all cases of NPC-related sixth nerve palsy receiving botulinum toxin injection in the Hong Kong Eye Hospital between January 2009 and January 2016. Only cases with diplopia for at least 6 months; and failed a trial of Fresnel prism therapy were recruited. We excluded cases with prior strabismus surgery and multiple cranial nerve palsies. Patients were offered botulinum toxin injection as primary treatment for their strabismus and were given further injections or offered surgery if diplopia persisted. Success with botulinum toxin was defined as a final distant orthophoria of <15 PD in primary gaze, no diplopia in primary position, and no head turn, as measured 6 months after the last injection, without requiring a second treatment.

Results

A total of 25 patients were included in the study. All patients received concurrent chemo-radiotherapy for NPC. There was a statistically significant reduction in the mean deviation at distant after the last injection compared to that at presentation (P<0.001, Wilcoxin signed rank test). Overall, 7 patients (28%) achieved clinical success and 15 patients (64%) remained diplopia-free by repeated botulinum toxin injections alone. Nine patients went on to receive definitive surgery and all achieved good ocular alignment after surgery. Transient ptosis or vertical deviation was seen in 7 patients, which resolved within 3 months and no serious complications arose from the treatment in our series.

Conclusions

Botulinum toxin injection is a relatively less-invasive alternative to surgery that can be done under a topical anesthesia setting, which improves patient’s quality of life via reduction in diplopia. It is a recommendable initial option in patients with chronic nerve palsies who may have higher risks associated with strabismus surgery.

Introduction

Nasopharyngeal carcinoma (NPC) is endemic to Southeast Asia. It is one of the top 10 most common cancers and is a major cause of cancer deaths in Hong Kong.¹ The mainstay of treatment is radiotherapy or concurrent chemo-radiotherapy (CCRT).² Advancement in imaging and treatment modalities has resulted in a decline in the total mortality of the disease.³ However, diplopia caused by cranial nerves dysfunction, which occurs in about 1–5% of NPC patients, still remains as a major source of disturbance to quality of life.^{4, 5} Cranial nerves impairment can be caused by local invasion of tumor to the skull base and cavernous sinus; or is related to post-radiotherapy complications. Among them, sixth nerve palsy is relatively common, because of its proximity to skull base and its small size.⁶

Despite shielding of the eyes during radiotherapy, post-irradiation ischemic changes can occur not only in the form of radiation optic neuropathy or retinopathy but even in a delayed manner as an increased risk of anterior segment ischemia with routine strabismus surgery.⁷ Cranial neuropathies after NPC treatment such as bulbar nerve palsy;⁸ and poor systemic comorbidity would also increase the risk of general anaesthesia in this group of patients. Very often, this group of patients would prefer conservative management whenever possible.

Botulinum toxin injection into the medial rectus muscle in sixth nerve palsy has been proposed as an effective alternative to surgery. It has been shown to bring temporary relief of symptoms or even an increase in recovery rate of patients with sixth nerve palsy from many causes.⁹ However, the efficacy of botulinum toxin injection for strabismus secondary to nerve palsy caused by tumors, in particular NPC, has not been reported extensively. We observed that botulinum toxin injection should be a good alternative to improve quality of life in NPC patients who are not fit or not willing for strabismus surgery. We therefore reported our experience with botulinum toxin injection as a primary initial treatment for chronic sixth nerve palsy secondary to NPC or its treatment-related complications.

Materials and methods

This is a retrospective chart review, observational case series. All consecutive patients receiving botulinum toxin injection in Hong Kong Eye Hospital were identified between January 2009 and January 2016. Inclusion criteria were as follows: (1) sixth nerve palsy resulted from NPC and its related treatment; (2) duration of symptoms for more than 6 months; (3) no prior history of strabismus; (4) diplopia at primary gaze at 6 m; (5) failure of Fresnel prism therapy; and (6) in remission and not on active treatment for underlying NPC. Patients suffered from multiple cranial nerve palsies, or those with follow-up after botulinum toxin injection <6 months were excluded.

The following data were collected for analysis: date of birth; laterality; date of diagnosis for NPC; age at tumor diagnosis; date of surgery for tumor; type of treatment; date of onset of the sixth nerve palsy; date of the first eye examination; date of the last eye examination; angle of deviation at 6 m in the primary position was recorded in prism diopters both before intervention and at follow-up after each intervention. Monocular abduction deficit was recorded on a scale described by Scott and Kraft:¹⁰ 0 (normal); −1 (to 75% full rotation); −2 (to 50% full rotation); −3 (to 25% full rotation); −4 (to midline); and −5 (inability to abduct to the midline). The date of botulinum toxin treatment, number of botulinum toxin injections, and any strabismus surgeries received were all retrieved.

Definition

Treatment success for sixth nerve palsy was defined as an esophoria <15 PD in primary gaze, no diplopia in primary position at distant fixation, and no abnormal head posture at the end of follow-up period (at least 6 months after receiving the last injection). Treatment failure was defined as failure to achieve the above goals or the need of a second intervention or change in management to achieve the above goals.

Surgical technique

Botulinum toxin (Botox onabotulinumtoxinA, Allergan, Dublin, Republic of Ireland) injection was done under topical anesthesia. A unit of 100 U botulinum toxin was reconstituted with 4 ml saline to produce 2.5 U botulinum toxin in 0.1 ml for the preparation. Dosage of injection depends on the angle of deviation: (1) 1.25−2.5 U to one muscle if the deviation was <20 PD; and (2) 2.5–5.0 U to one or two muscles (depending on prism diopters and surgeon preference) if the deviation was ranging at 20−50 PD. Under electromyography guidance (Clavis, The Dantec Clavis device, distributed by Natus Medical Incorporated, Pleasanton, California, United States), botulinum toxin was injected with a 27-gauge, 1.5-inch needle at ~1 cm posterior to the insertion of the medical rectus muscle on the globe. All patients received tobrex (tobramycin 3 mg/ml, Alcon, Fort Worth, Texas, USA) eye drops one drop every 6 h for 1 week postoperatively. Patients were followed up at 1 week, 2 months, and 6 months after each injection.

Statistical analysis

Statistical analyses were performed using SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA). Descriptive statistics of primary and secondary outcome measures in both groups were reported. Group median was compared with Wilcoxon rank sum test for independent data and Wilcoxon signed ranks test for paired data. Success rates were evaluated using Fisher’s exact test. A P-value of <0.05 was considered statistically significant.

The study was approved by the local institutional research board and was conducted in accordance with the Declaration of Helsinki.

Results

A total of 25 patients were recruited during the study period. All patients had been treated for NPC with either radiotherapy or CCRT. There was a male predominance (male : female=22 : 3) consistent with data from the HK Cancer Registry.¹ Mean age at presentation was 53.3±8.84 years (range 35−69 years). The mean follow-up duration from presentation to last follow-up was 39 months (range 8 months–7 years). By the end of the follow-up period 11 patients had passed away due to co-existing systemic disease.

All patients had diplopia. The sixth nerve palsies were bilateral in 11 patients and unilateral in 14. The mean of primary deviation at distance was 39.3±16.4 PD (range 10−80 PD) at presentation. All patients failed a previous trial of Fresnel prism therapy. Among all patients, 8 of them received botulinum toxin injection as initial management because they were not fit for strabismus surgery due to poor comorbid condition. The remaining 17 patients were physically fit for surgery, but they all preferred botulinum toxin therapy as initial treatment. Patient demographics and treatment details are listed in Table 1.

Table 1. Patient demographics and treatment details.

Case	Age	Sex	Systemic condition/RT complication	NPC treatment	Duration	Laterality	EOM function	Pre-op deviation (PD)	Reason for Botox trial (after failed FP)	Dose (U)	No. of injection	Deviation 6/12 after last Botox	Diplopia after Botox	Final EOM limitation	Definitive surgery	Complication with Botox	Change in deviation	Mortality
1	48	M	HT	ChemoRT 2009	1 year	LE	−1	18	Not keen for OT	3	2	6	−	−0.5	—	—	12
2	59	M	Liver and bone metastasis	Radical RT 2005	1 year	LE	4	80	Poor systemic condition	5	1	70	+	−4	BE SR+IR to LR transposition+L MR recession 2/12/11	—	10	Passed away in 2012
3	65	M	Temporal obe necrosis, panhypopituitarism, deafness, CVA, HT	RT 1985	>15 years	BE	−3	30	Poor systemic condition	5	4	6	−	−2	—	—	24	Passed away in 2015
4	48	M	Hypothyroidism, pancytopenia, second primary—CA tongue	RT 1996	2 years	LE	−2	45	Not keen for OT Failed FP	5	4	8	−	−1	—	—	37
5	48	M	NPC with skull base and prepontine region involvement. History of DVT	RT 2007	2 years	LE	−2	45	Poor systemic condition	5	1	40	+	−4	—	—	5	Passed away in 2011
6	58	M	IHD, CVA	RT 1987	1 year	RE	−1	45	Not keen for OT	5	3	12	+	−2	—	Transient ptosis	33
7	47	M	Hypothyroidism, mild swallowing impairment	Radical RT 2002	4 years	RE	−1	18	Not keen for OT	2.5	12	10	−	−1	BE MR recession 15/6/16	Transient ptosis	8
8	51	M	Lung metastasis, hypothyroidism	Radical RT 2002	5 years	RE	−1	35	Not keen for OT	5	9	35	+	−2	BE IR/ SR transposition+MR recession 9/8/13	Transient ptosis	0	Passed away in 2015
9	54	M	Hearing impairment	Radical RT 1982	4 years	LE	−2	30	Not keen for OT	2.5	9	30	+	−2	—	—	0
10	64	M	CVA, swallowing impairment	RT 1989, 2007	1 year	RE	−2	45	Poor systemic condition	2.5	1	25	+	−1	—	—	20	Passed away in 2009
11	34	M	NPC with skull base, sinus, brain and lung metastasis	Palliative RT 2009	1 year	BE	−1	50	Poor systemic condition	5	1	45	+	−2	—	—	5	Passed away in 2012
12	61	M	Bone metastasis, Hx of BCC, R carotid stenosis	palliative RT 1999	1 year	BE	−1	35	Poor systemic condition	2.5	1	8	−	−1	—	—	27	Passed away in 2011
13	53	F	Hypothyroidism, temporal lobe necrosis	Radical RT 1990, 1993	1 year	BE	−1	20	Not keen for OT	2.5	1	20	+	−2	—	Transient vertical deviation	0
14	50	M	Lipids	RT 1991	10 years	BE	−2	45	Not keen for OT	5	3	20	+	−2	BE SR+IR transpose to LR and BE MR recession	—	25
15	53	M	Hypothyroidism, R carotid stenosis	NPC with RT 1984	2 years	BE	−2	45	Not keen for OT	5	2	45	+	−2	BE SR/IR trasnfer±R MR recession±L SR / IR transfer	—	0
16	45	M	Hypothyroidism, persistent hypokalemia and hypomagnesiumia after chemotherapy	ChemoRT 2007	2 years	LE	−1	35	Not keen for OT	5	1	25	+	−2	—	—	10
17	59	F	Hypothyroidism, DM, lipid	RT 1982, 1987 (palliative intent)	2 years	BE	−2	30	Not keen for OT	5	3	25	+	−2	BE MR recession 2/10/15	—	5
18	44	M	Depression	ChemoRT 2008	2 years	BE	−1	16	Not keen for OT	2.5	1	10	−	−1	—	—	6
19	62	M	Second primary HCC, HBV carrier	Radical RT 2009	1 year	RE	−4	80	Not keen for OT	5	1	80	+	−4	RE SR+IR to LR half tendon transfer±MR recession	—	0
20	53	M	Hypothyroidism, Dysphagia, Hx of SAH with LP shunt in 2008	RT 1985, 1992	6 months	RE	−1	20	Poor systemic condition	2.5	1	12 (EP)	−	−1	—	—	8	Passed away in 2014
21	69	F	Hearing loss	RT 1994	6 months	LE	−3	55	Not keen for OT	5	4	15	+	−1	—	Transient vertical deviation	40	Passed away in 2013
22	49	M	Panhypopituitarism, HT, CVA	Radical RT 1998	1 year	BE	3	35	Not keen for OT	5	1	30	+	−3	RE SR/IR half split tendon transfer+MR recession 6.5 mm BE	Transient ptosis	5	Passed away in 2014
23	62	M	Panhypopituitarism, anemia	RT 1982, 1994	2 years	BE	−2	45	Not keen for OT	5	5	40	+	−2	—	—	5
24	61	M	Baroreceptor failure with labile BP	ChemoRT 2009, 2012	1 year	RE	−2	35	Not keen for OT	5	1	35	+	−3	SR/IR transposition±R MR recession	Transient vertical deviation	0	Passed away in 2014
25	35	M	Temporal lobe necrosis with seizures, hypopituitarism, dysphagia	RT 1979	5 years	BE	−2	45	Poor systemic condition	5	1	45	+	−2	—	—	0

Overall effect of botulinum toxin

Patients received a mean of 3±3.0 injections (range 1−12). The mean of primary deviation was 33.3±20.8, 31.3±14.7, and 28.08±19.34 PD at 6 months after the first injection, 6 months after second injection, and 6 months after third injection, respectively. There was a statistically significant reduction in the mean deviation at distant after the last injection compared to presentation (P<0.001, Wilcoxin signed rank test).

Reduction in angle of deviation after each injection

After the first injection, an immediate improvement was seen with the mean reduction in angle of deviation of 22.6±12.9 PD at 1 week postoperatively. In all, 19 out of 25 patients reported free of diplopia within 2 months after the first injection. However, the results worn off by 6 months postoperatively with a mean reduction in angle of deviation dropping to 5.87±6.47. A total of 12 patients went on to receive the second botulinum toxin injection with reduction in the angle of deviation being 24.8±11.4 PD at 2 months post injection. By 6 months post injection the results weaned off with a mean reduction in angle of deviation of 6±5.9 PD. Similar figures were seen after the third injection where the mean reduction in angle of deviation was 27.2±14.0 and 6.2±6.49 PD at 1 week and 6 months after operation, respectively.

Treatment success

Out of the 25 patients, 16 cases (64%) remained diplopia-free by repeated botulinum toxin injections alone. Among them, 7 cases (28%) fulfilled the definition of clinical success. The remaining 9 cases eventually required strabismus surgery after failure of botulinum toxin therapy. Among these 9 patients, 7 had angles of deviation >30 PD on presentation, and had poor response to botulinum toxin injection. They all received muscle transposition surgeries as the definite treatment. The remaining 2 patients had moderate deviation of 15−30 PD on presentation and had partial response to botulinum toxin. They received MR recession surgery alone. All 9 cases achieved good ocular alignment after surgery. On the other hand, the remaining 9 patients who did not fulfill the criteria for treatment success declined strabismus surgery and opted for repeated botulinum toxin injections to maintain diplopia-free status.

Complications

Transient ptosis (resolved within 3 months) was seen in four patients after the first injection, but none in subsequent injections despite botulinum toxin therapy at same dosage. Transient vertical deviation <6 PD (resolved within 3 months) was seen in another three patients after the first injection. No serious complications were reported in our series.

Preoperative and intraoperative factors for treatment success

We performed univariate analysis to compare the differences in characteristics between the success group with botulinum toxin therapy alone and non-success group (Table 2). Preoperative deviation was significantly lower in the success group compared with non-success group (26.00±11.0 PD vs 44.4±15.4, P=0.01, Wilcoxon rank sum test). The corresponding dosage of botulinum toxin therapy was also lower in the success group compared with non-success group, which approached statistical significance (3.29±1.19 vs 4.58±0.96, P=0.05, Wilcoxon rank sum test). There was no significant difference between groups in terms of age of presentation, duration of palsy, EOM function, or number of injections received.

Table 2. Univariate analysis to compare the differences in characteristics between the success group with botulinum toxin therapy alone and non-success group.

	No success (18)	Success (7)	P-valuea
Age (year)	53.67±9.38	52.29±7.87	0.46
Duration of palsy (year)	2.36±2.35	3.64±5.137	0.88
Pre-op deviation	44.4±15.42	26.00±10.97	0.01
EOM function	2.11±0.90	1.43±0.79	0.09
Number of injection	2.67±2.61	3.57±3.95	0.57
Dosage	4.58±0.96	3.29±1.19	0.05

^aMann–Whitney U-test.

Discussion

We reported the efficacy of botulinum toxin injection as initial therapy in a cohort of chronic sixth nerve palsy secondary to NPC. Notably, there was persistent reduction in angle of deviation after repeated botulinum toxin injections. About 28% and 64% of patients can achieve clinical success and diplopia-free by repeated botulinum toxin injections, respectively. Patient with a smaller preoperative angle of deviation has a higher chance of treatment success. NPC is endemic in our locality, and that this group of patient has an increased risk of strabismus surgery because of poor systemic comorbidity. Therefore, sparing these patients from surgical therapy is important and highly relevant.

Botulinum toxin was first used for the treatment of strabismus in the early 1980s. Over the past 20 years, its use in strabismus has rapidly expanded to include the treatment of various nerve palsies, dysthyroid strabismus, and augmentation of strabismus surgery, etc.¹¹ The effect of botulinum toxin on muscle paralysis is believed to be transient, which is typically seen within 2–4 days and is expected to wean off 6–12 weeks after injection. However, some possible long-term effects of botulinum toxin have been reported, leading to its use as a sole treatment for strabismus by others.¹²

The proposed mechanism of botulinum toxin in chronic nerve palsy, as compared to prevention of muscle contracture in acute nerve palsies, has been postulated to be related to a structural alteration in the rectus muscle produced by chemodenervation. The animal model by Spencer and McNeer¹³ revealed a permanent reduction of muscle fiber cross-sectional area in injected muscles compared to non-injected ones. This would lead to a permanent change in the muscular length tension curves and fatigue characteristics, resulting in change in ocular alignment, even after the wean off of botulinum toxin effect. This after-effect is believed to be augmented by the presence of motor fusion.¹¹ Our study concurred with previous reports on the after-effect of botulinum toxin in cases of chronic nerve palsy. We demonstrated a significant smaller angle of deviation at least 3 months after the last injection of botulinum toxin when compared with that at presentation. Although this effect alone could not lead to clinical success in majority of cases, our reported of 28% success should also serve as an important reference to eligible patients. Similarly, Repka et al¹⁴ and Biglan et al¹⁵ conducted studies on the use of botulinum toxin in the initial management of chronic sixth nerve palsies. At 6 months of follow-up after last injection, 41% and 64% of patients in their studies showed at least 50% reduction in angle of deviation, respectively. In both studies, botulinum toxin therapy was not as effective as surgery, but was still encouraging. On the other hand, another prospective study by Holmes et al¹⁶ reported that only 1 out of 10 patients with chronic sixth nerve palsy was successfully managed with botulinum toxin alone. However, it is difficult to directly compare the success rates from various studies due to different methodology and definitions of success. The relatively low success from the study by Holmes et al¹⁶ concluded that botulinum toxin alone is less likely to produce promising results in chronic sixth nerve palsy and that at least two procedures are necessary to regain single binocular vision in this group. In our series, nine cases eventually required strabismus surgery after poor response to botulinum toxin therapy. Among them, seven cases with >30 PD presenting deviation with poor response to botulinum toxin treatment received transposition surgery. However, in two cases with partial response to botulinum toxin but whom still complained of diplopia, we were able to achieve good clinical outcome with a simpler single muscle MR recession procedure. This highlights another benefit of an initial botulinum toxin trial—even if monotherapy with botulinum toxin could not bring about treatment success, presence of partial response, or possible resultant reduction in overall deviation after the therapy may prompt the choice of a simpler recession procedure over a more complicated transposition surgery, which would involve operation on more muscles and consequently incur higher risk.

A previous study of 95 patients undergoing at least eight botulinum toxin injections for strabismus demonstrated an overall trend of fewer injections required with time.¹⁷ However, our study did not demonstrate an association between the number of botulinum toxin injection and treatment success. In addition, increase in dosage of botulinum toxin per injection also did not lead to increase in success. In contrary, we observed that the dosage of botulinum toxin was lower in the success group comparing to the non-success group (3.29 vs 4.58 U). This could be explained by the fact that lower dosage of botulinum toxin is required for smaller preoperative angles of deviation, which is an important factor for treatment success. Horgan et al¹⁷ reported no adverse outcomes from their long-term botulinum toxin therapy, concluding that botulinum toxin therapy is an appropriate and safe option for strabismus patients who do not want to undergo further surgery. Transient ptosis or vertical deviation was observed in seven cases with the first injection, the occurrence was consistent with literature.¹⁸ No serious ocular or systemic complications from the botulinum toxin intervention was reported in our series.

Importantly, we have demonstrated that a smaller preoperative deviation may lead to higher treatment success with botulinum toxin alone. The ‘after-effect’ of botulinum toxin on medial rectus was postulated to be dependent on the opposing force from the lateral rectus, which would be absent in complete sixth nerve palsy.¹¹ Hence, we believe that the best outcomes for botulinum toxin injection in chronic sixth nerve palsy are those with partially recovered or fully recovered lateral rectus function, with mild contracture of the medial rectus, and mild to moderate deviation (15−30 PD) at primary. In our series, other factors including age of presentation and duration of the chronic nerve palsy did not influence the success.

Despite the improving life expectancy, NPC survivors continue to suffer from long-term complications or side effects of radiotherapy or CCRT.¹⁹ In our series, 8 patients were deemed systemically unfit to tolerate a major surgery, and by the time of conclusion of this study, 11 patients passed away due to systemic diseases. Botulinum toxin, being a relatively simple and less-invasive procedure with a low complication rate, is a good initial therapy in the management of diplopia and esodeviation in patients with debilitating systemic conditions or those at a higher risk of squint surgery.

Our study is limited by its retrospective nature. In addition, our sample size is relatively small, which might affect the power of our statistical analysis. Nevertheless, our cohort is the largest report of its kind in the literature.

Conclusion

Botulinum toxin is a recommendable initial option in patients with chronic sixth nerve palsy secondary to NPC, who are at a higher risk of anterior segment ischemia with strabismus surgery⁷ and whose nerve palsy has a lower chance of spontaneous recovery. It is a relatively less-invasive alternative to surgery and facilitates earlier regaining of binocularity and reduction of diplopia, which may improve patient’s quality of life.